Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Advanced Cancer × Nivolumab × Clear all

Phase

Phase 1 6 Phase 1/2 5 Phase 2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 21 Melanoma 20 Carcinoma, Renal Cell 12 Stomach Neoplasms 8 Lung Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 5 Brain Neoplasms 5 Mesothelioma 4 Kidney Neoplasms 4 Carcinoma, Hepatocellular 4 Adenocarcinoma Of Esophagus 4 Urinary Bladder Neoplasms 3 Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Various Advanced Cancer 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Mesothelioma, Malignant 2 Liver Neoplasms 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Carcinoma 2 Anus Neoplasms 2 Adenocarcinoma 2 von Hippel-Lindau Disease 1 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Thoracic Neoplasms 1

Interventions

Quality of Life 1 Patient Readmission 1 Palliative Care 1 Olanzapine 1 Nivolumab 1 Needs Assessment 1 Coping Skills 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02743494 2025-11-18

CheckMate 577

Bristol-Myers Squibb

Phase 3 Completed

794 enrolled 13 charts 1 FDA

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡